JP2007530068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530068A5 JP2007530068A5 JP2007505621A JP2007505621A JP2007530068A5 JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5 JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- hosm
- interaction
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims 25
- 108091033319 polynucleotide Proteins 0.000 claims 25
- 239000002157 polynucleotide Substances 0.000 claims 25
- 230000001225 therapeutic effect Effects 0.000 claims 23
- 230000003993 interaction Effects 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 241000282414 Homo sapiens Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims 5
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims 5
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 5
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims 5
- 238000002965 ELISA Methods 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407197A GB0407197D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407193.2 | 2004-03-30 | ||
| GB0407193A GB0407193D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407197.3 | 2004-03-30 | ||
| PCT/GB2005/001147 WO2005095457A2 (en) | 2004-03-30 | 2005-03-29 | Immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530068A JP2007530068A (ja) | 2007-11-01 |
| JP2007530068A5 true JP2007530068A5 (https=) | 2008-04-24 |
| JP4809828B2 JP4809828B2 (ja) | 2011-11-09 |
Family
ID=35064447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505621A Expired - Fee Related JP4809828B2 (ja) | 2004-03-30 | 2005-03-29 | 免疫グロブリン |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7858753B2 (https=) |
| EP (2) | EP1730191B1 (https=) |
| JP (1) | JP4809828B2 (https=) |
| KR (1) | KR100942849B1 (https=) |
| AR (1) | AR048516A1 (https=) |
| AT (1) | ATE515515T1 (https=) |
| AU (1) | AU2005229457B2 (https=) |
| BR (1) | BRPI0509367A (https=) |
| CA (1) | CA2562953A1 (https=) |
| CY (1) | CY1112192T1 (https=) |
| DK (1) | DK1730191T3 (https=) |
| HR (1) | HRP20110657T1 (https=) |
| IL (1) | IL178119A0 (https=) |
| MA (1) | MA28541B1 (https=) |
| NO (1) | NO20064886L (https=) |
| NZ (1) | NZ550225A (https=) |
| PE (1) | PE20060287A1 (https=) |
| PL (1) | PL1730191T3 (https=) |
| PT (1) | PT1730191E (https=) |
| RU (5) | RU2429245C2 (https=) |
| SG (1) | SG151292A1 (https=) |
| SI (1) | SI1730191T1 (https=) |
| TW (1) | TWI365746B (https=) |
| WO (1) | WO2005095457A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| TWI422387B (zh) | 2006-05-25 | 2014-01-11 | Glaxo Group Ltd | 免疫球蛋白 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
| BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| WO2010027797A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US8309688B2 (en) * | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| US9115200B2 (en) | 2010-02-04 | 2015-08-25 | Toray Industries, Inc. | Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1 |
| RU2603742C2 (ru) | 2010-02-04 | 2016-11-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
| CA2788545C (en) | 2010-02-04 | 2019-03-26 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| DK2532366T3 (da) | 2010-02-04 | 2017-01-02 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| KR101920250B1 (ko) * | 2010-10-13 | 2018-11-20 | 얀센 바이오테크 인코포레이티드 | 인간 온코스타틴 m 항체 및 이용 방법 |
| TWI504609B (zh) * | 2010-11-23 | 2015-10-21 | Glaxo Group Ltd | 抗原結合蛋白質 |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| EP2740794B1 (en) | 2011-08-04 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| ES2739612T3 (es) | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
| WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
| JP6107654B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
| WO2013147176A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| WO2016046738A1 (en) * | 2014-09-24 | 2016-03-31 | Università Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
| AU2016211950A1 (en) * | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| MX2018011109A (es) | 2016-03-28 | 2018-11-09 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| EP3788079A4 (en) | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| FR3090637A1 (fr) * | 2018-12-21 | 2020-06-26 | Universite De Poitiers | Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations. |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
| TWI904261B (zh) | 2020-10-19 | 2025-11-11 | 美商碩騰服務公司 | 犬及貓抑瘤素M受體β之抗體及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| ES2196002T3 (es) | 1991-07-25 | 2003-12-16 | Idec Pharma Corp | Anticuerpos recombinantes para terapia humana. |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
-
2005
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en not_active Ceased
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en not_active Expired - Lifetime
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active Expired - Fee Related
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
-
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
-
2009
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
-
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
-
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530068A5 (https=) | ||
| RU2006134477A (ru) | Иммуноглобулины | |
| JP2024156852A (ja) | 結合タンパク質及びその使用方法 | |
| CN109517065B (zh) | Il-18结合分子 | |
| US20240353422A1 (en) | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP6513657B2 (ja) | Il−17a結合剤およびその用途 | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2021101720A5 (https=) | ||
| KR20180048712A (ko) | Tl1a에 특이적으로 결합하는 항체 | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| EP2771362A1 (en) | Immunobinders directed against tnf | |
| JP2020521504A (ja) | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| CN113677701B (zh) | 产生亲合结合多特异性抗体的方法 | |
| TW202334220A (zh) | 人類腫瘤壞死因子α抗體 | |
| WO2013186630A2 (en) | Humanized antibodies to ca215 | |
| GB2600273A (en) | Antibody to leptin receptor | |
| US20190225680A1 (en) | Tenascin Epitope and Antibodies Thereto | |
| US10584175B2 (en) | FN14-binding proteins and uses thereof | |
| CN114106163A (zh) | SARS-CoV-2病毒中和抗体及其用途 | |
| US20260116963A1 (en) | Anti-il-13 antibodies and methods of use thereof | |
| AU2024319932A1 (en) | Btn3a-binding protein and medical uses thereof | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
| CN120476139A (zh) | 抗tslp抗体及其应用 |